Advertisement

The Influence of Naproxen on Biological Factors in Leukocyte-Rich Platelet-Rich Plasma: A Prospective Comparative Study

Published:November 21, 2018DOI:https://doi.org/10.1016/j.arthro.2018.07.030

      Purpose

      To quantify and compare normative catabolic and anabolic factor concentrations in leukocyte-rich platelet-rich plasma (LR-PRP) at various time points, including baseline, 1 week after initiating naproxen use, and after a 1-week washout period.

      Methods

      Asymptomatic healthy donors aged between 18 and 70 years were recruited (average age, 36.6 years; range, 25-64 years). Subjects were excluded from the study if they were actively taking any prescribed medications or nonsteroidal anti-inflammatory drugs (NSAIDs) or if they had any of the following at present or previously: blood or immunosuppression disorders, cancer, osteonecrosis, rheumatoid arthritis, avascular necrosis, NSAID intolerance, gastrointestinal or peptic ulcer disease, or kidney dysfunction. The anabolic factors vascular endothelial growth factor, fibroblast growth factor 2, platelet-derived growth factor AB (PDGF-AB), and platelet-derived growth factor AA (PDGF-AA) and the catabolic factors interleukin (IL) 1β, IL-6, IL-8, and tumor necrosis factor α in LR-PRP were measured. Peripheral blood was drawn at 3 time points: baseline, after 1 week of naproxen use, and after a 1-week washout period.

      Results

      The angiogenic factors PDGF-AA (44% decrease in median) and PDGF-AB (47% decrease) significantly declined from baseline (P < .05) after 1 week of naproxen use. There was a significant recovery (P < .05) of PDGF-AA (94% increase) and PDGF-AB (153% increase) levels after the 1-week washout period, with a return to baseline levels. The catabolic factor IL-6 also had a significant decline from baseline (77% decrease in median, P < .05) after 1 week of naproxen use. After a 1-week washout period, the IL-6 level was similar to the baseline level (130% increase, P < .05).

      Conclusions

      Naproxen use diminished several biological factors in LR-PRP; however, a 1-week washout period was sufficient for the recovery of PDGF-AA, PDGF-AB, and IL-6 to return to baseline levels. Tumor necrosis factor α, IL-1β, IL-8, vascular endothelial growth factor, and fibroblast growth factor 2 did not show differences between the 3 time points of data collection. Discontinuing NSAIDs for a minimum of 1 week before LR-PRP treatment may improve certain biological factor levels.

      Level of Evidence

      Level II, prospective comparative study.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Arthroscopy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Woolf A.D.
        Global burden of osteoarthritis and musculoskeletal diseases.
        BMC Musculoskeletal Disorders. 2015; 16: S3
        • Helmick C.G.
        • Felson D.T.
        • Lawrence R.C.
        • et al.
        Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.
        Arthritis Rheum. 2008; 58: 15-25
        • Yelin E.
        • Weinstein S.
        • King T.
        The burden of musculoskeletal diseases in the United States.
        Semin Arthritis Rheum. 2016; 46: 259-260
        • Yelin E.
        Cost of musculoskeletal diseases: Impact of work disability and functional decline.
        J Rheumatol Suppl. 2003; 68: 8-11
        • Mazzocca A.D.
        • McCarthy M.B.
        • Chowaniec D.M.
        • et al.
        The positive effects of different platelet-rich plasma methods on human muscle, bone, and tendon cells.
        Am J Sports Med. 2012; 40: 1742-1749
        • de Mos M.
        • van der Windt A.E.
        • Jahr H.
        • et al.
        Can platelet-rich plasma enhance tendon repair? A cell culture study.
        Am J Sports Med. 2008; 36: 1171-1178
        • Laumonier T.
        • Menetrey J.
        Muscle injuries and strategies for improving their repair.
        J Exp Orthop. 2016; 3: 15
        • Huard J.
        • Li Y.
        • Fu F.H.
        Muscle injuries and repair: Current trends in research.
        J Bone Joint Surg Am. 2002; 84: 822-832
        • Evanson J.R.
        • Guyton M.K.
        • Oliver D.L.
        • et al.
        Gender and age differences in growth factor concentrations from platelet-rich plasma in adults.
        Mil Med. 2014; 179: 799-805
        • Hire J.M.
        • Evanson J.L.
        • Johnson P.C.
        • et al.
        Variance of matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) concentrations in activated, concentrated platelets from healthy male donors.
        J Orthop Surg Res. 2014; 9: 29
        • Whitney K.
        • Bolia I.
        • Chahla J.
        • et al.
        Physiology and homeostasis of musculoskeletal structures, injury response, healing process, and regenerative medicine approaches.
        2017
        • Reed G.L.
        • Fitzgerald M.L.
        • Polgar J.
        Molecular mechanisms of platelet exocytosis: Insights into the "secrete" life of thrombocytes.
        Blood. 2000; 96: 3334-3342
        • Curatolo M.
        • Bogduk N.
        Pharmacologic pain treatment of musculoskeletal disorders: Current perspectives and future prospects.
        Clin J Pain. 2001; 17: 25-32
        • Schippinger G.
        • Pruller F.
        • Divjak M.
        • et al.
        Autologous platelet-rich plasma preparations: Influence of nonsteroidal anti-inflammatory drugs on platelet function.
        Orthop J Sports Med. 2015; 3 (2325967115588896)
        • Schafer A.I.
        Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis.
        J Clin Pharmacol. 1995; 35: 209-219
        • Hanson S.R.
        • Slichter S.J.
        Platelet kinetics in patients with bone marrow hypoplasia: Evidence for a fixed platelet requirement.
        Blood. 1985; 66: 1105-1109
        • Paez Espinosa E.V.
        • Murad J.P.
        • Khasawneh F.T.
        Aspirin: Pharmacology and clinical applications.
        Thrombosis. 2012; 2012: 173124
        • Di Matteo B.
        • Filardo G.
        • Lo Presti M.
        • Kon E.
        • Marcacci M.
        Chronic anti-platelet therapy: A contraindication for platelet-rich plasma intra-articular injections?.
        Eur Rev Med Pharmacol Sci. 2014; 18: 55-59
        • Inaoka M.
        • Kimishima M.
        • Takahashi R.
        • Shiohara T.
        Non-steroidal anti-inflammatory drugs selectively inhibit cytokine production by NK cells and gamma delta T cells.
        Exp Dermatol. 2006; 15: 981-990
        • Castano E.
        • Bartrons R.
        • Gil J.
        Inhibition of cyclooxygenase-2 decreases DNA synthesis induced by platelet-derived growth factor in Swiss 3T3 fibroblasts.
        J Pharmacol Exp Ther. 2000; 293: 509-513
        • Kawaguchi H.
        • Chikazu D.
        • Nakamura K.
        • Kumegawa M.
        • Hakeda Y.
        Direct and indirect actions of fibroblast growth factor 2 on osteoclastic bone resorption in cultures.
        J Bone Miner Res. 2000; 15: 466-473
        • Tarnawski A.S.
        • Jones M.K.
        Inhibition of angiogenesis by NSAIDs: Molecular mechanisms and clinical implications.
        J Mol Med (Berl). 2003; 81: 627-636
        • Su B.
        • O'Connor J.P.
        NSAID therapy effects on healing of bone, tendon, and the enthesis.
        J Appl Physiol (1985). 2013; 115: 892-899
        • Martinez Cairo S.
        • Salgado Legorreta C.
        • Martinez Zurita F.
        Effect of naproxen on serum concentrations of IL-I, IL-6, and TNF in patients with osteoarthritis.
        Rev Alerg Mex. 2001; 48 ([in Spanish]): 119-122
        • Blom M.A.
        • van Twillert M.G.
        • de Vries S.C.
        • et al.
        NSAIDS inhibit the IL-1 beta-induced IL-6 release from human post-mortem astrocytes: The involvement of prostaglandin E2.
        Brain Res. 1997; 777: 210-218
        • Housby J.N.
        • Cahill C.M.
        • Chu B.
        • et al.
        Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes.
        Cytokine. 1999; 11: 347-358
        • Sanchez C.
        • Mateus M.M.
        • Defresne M.P.
        • Crielaard J.M.
        • Reginster J.Y.
        • Henrotin Y.E.
        Metabolism of human articular chondrocytes cultured in alginate beads. Longterm effects of interleukin 1beta and nonsteroidal antiinflammatory drugs.
        J Rheumatol. 2002; 29: 772-782
        • Page T.H.
        • Turner J.J.
        • Brown A.C.
        • et al.
        Nonsteroidal anti-inflammatory drugs increase TNF production in rheumatoid synovial membrane cultures and whole blood.
        J Immunol. 2010; 185: 3694-3701
        • Gross G.J.
        • Moore J.
        Effect of COX-1/COX-2 inhibition versus selective COX-2 inhibition on coronary vasodilator responses to arachidonic acid and acetylcholine.
        Pharmacology. 2004; 71: 135-142
        • Knijff-Dutmer E.A.
        • Kalsbeek-Batenburg E.M.
        • Koerts J.
        • van de Laar M.A.
        Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis.
        Rheumatology (Oxford). 2002; 41: 458-461
        • Duggan K.C.
        • Walters M.J.
        • Musee J.
        • et al.
        Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen.
        J Biol Chem. 2010; 285: 34950-34959
        • Foster T.E.
        • Puskas B.L.
        • Mandelbaum B.R.
        • Gerhardt M.B.
        • Rodeo S.A.
        Platelet-rich plasma: From basic science to clinical applications.
        Am J Sports Med. 2009; 37: 2259-2272
        • von Elm E.
        • Altman D.G.
        • Egger M.
        • et al.
        The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies.
        Int J Surg. 2014; 12: 1495-1499
        • Mannava S.
        • Chahla J.
        • Geeslin A.G.
        • et al.
        Platelet-rich plasma augmentation for hip arthroscopy.
        Arthrosc Tech. 2017; 6: e763-e768
        • Mukherjee S.
        • Katki K.
        • Arisi G.M.
        • Foresti M.L.
        • Shapiro L.A.
        Early TBI-induced cytokine alterations are similarly detected by two distinct methods of multiplex assay.
        Front Mol Neurosci. 2011; 4: 21
        • Robich M.P.
        • Chu L.M.
        • Feng J.
        • et al.
        Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on ischemic myocardium.
        J Thorac Cardiovasc Surg. 2010; 140: 1143-1152
        • Dikman A.
        • Sanyal S.
        • Von Althann C.
        • et al.
        A randomized, placebo-controlled study of the effects of naproxen, aspirin, celecoxib or clopidogrel on gastroduodenal mucosal healing.
        Aliment Pharmacol Ther. 2009; 29: 781-791
        • Murray I.R.
        • Geeslin A.G.
        • Goudie E.B.
        • Petrigliano F.A.
        • LaPrade R.F.
        Minimum information for studies evaluating biologics in orthopaedics (MIBO): Platelet-rich plasma and mesenchymal stem cells.
        J Bone Joint Surg Am. 2017; 99: 809-819
        • Murray I.R.
        • LaPrade R.F.
        Platelet-rich plasma: Renewed scientific understanding must guide appropriate use.
        Bone Joint Res. 2016; 5: 92-94
        • Castillo T.N.
        • Pouliot M.A.
        • Kim H.J.
        • Dragoo J.L.
        Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems.
        Am J Sports Med. 2011; 39: 266-271
        • Oh J.H.
        • Kim W.
        • Park K.U.
        • Roh Y.H.
        Comparison of the cellular composition and cytokine-release kinetics of various platelet-rich plasma preparations.
        Am J Sports Med. 2015; 43: 3062-3070
        • Magalon J.
        • Bausset O.
        • Serratrice N.
        • et al.
        Characterization and comparison of 5 platelet-rich plasma preparations in a single-donor model.
        Arthroscopy. 2014; 30: 629-638
        • LaPrade R.F.
        • Geeslin A.G.
        • Murray I.R.
        • et al.
        Biologic treatments for sports injuries II think tank-current concepts, future research, and barriers to advancement, part 1: Biologics overview, ligament injury, tendinopathy.
        Am J Sports Med. 2016; 44: 3270-3283
        • Murray I.R.
        • LaPrade R.F.
        • Musahl V.
        • et al.
        Biologic treatments for sports injuries II think tank-current concepts, future research, and barriers to advancement, part 2: Rotator cuff.
        Orthop J Sports Med. 2016; 4 (2325967116636586)
        • Zlotnicki J.P.
        • Geeslin A.G.
        • Murray I.R.
        • et al.
        Biologic treatments for sports injuries II think tank-current concepts, future research, and barriers to advancement, part 3: Articular cartilage.
        Orthop J Sports Med. 2016; 4 (2325967116642433)
        • Mussano F.
        • Genova T.
        • Munaron L.
        • Petrillo S.
        • Erovigni F.
        • Carossa S.
        Cytokine, chemokine, and growth factor profile of platelet-rich plasma.
        Platelets. 2016; 27: 467-471
        • Sundman E.A.
        • Cole B.J.
        • Fortier L.A.
        Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma.
        Am J Sports Med. 2011; 39: 2135-2140
        • Miroshnychenko O.
        • Chang W.T.
        • Dragoo J.L.
        The use of platelet-rich and platelet-poor plasma to enhance differentiation of skeletal myoblasts: Implications for the use of autologous blood products for muscle regeneration.
        Am J Sports Med. 2017; 45: 945-953
        • Braun H.J.
        • Kim H.J.
        • Chu C.R.
        • Dragoo J.L.
        The effect of platelet-rich plasma formulations and blood products on human synoviocytes: Implications for intra-articular injury and therapy.
        Am J Sports Med. 2014; 42: 1204-1210
        • Dragoo J.L.
        • Braun H.J.
        • Durham J.L.
        • et al.
        Comparison of the acute inflammatory response of two commercial platelet-rich plasma systems in healthy rabbit tendons.
        Am J Sports Med. 2012; 40: 1274-1281
        • Chen M.R.
        • Dragoo J.L.
        The effect of nonsteroidal anti-inflammatory drugs on tissue healing.
        Knee Surg Sports Traumatol Arthrosc. 2013; 21: 540-549
        • Amable P.R.
        • Carias R.B.
        • Teixeira M.V.
        • et al.
        Platelet-rich plasma preparation for regenerative medicine: Optimization and quantification of cytokines and growth factors.
        Stem Cell Res Ther. 2013; 4: 67

      Linked Article

      • Editorial Commentary: Platelet-Rich Plasma Details Are Critical to Outcome…Catching Is Always Better Than Fishing
        ArthroscopyVol. 35Issue 1
        • Preview
          The use of platelet-rich plasma (PRP) and the spectrum of orthobiological interventions has been a major innovation in orthopedic surgery and medicine. Biological-based therapies for musculoskeletal disorders and injuries have gained popularity in the past decade and created significant expectation as the future of sports medicine, based on theoretical advantages including minimal invasiveness, greater healing potential, faster recovery, and a less expensive alternative to surgery. These therapies for musculoskeletal intervention include PRP, bone marrow aspirate concentrate, cellular-based therapies, and tissue engineering.
        • Full-Text
        • PDF